{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.66","upperLimit":"15.08","value":"12.21"},{"groupId":"OG001","lowerLimit":"8.11","upperLimit":"10.74","value":"9.49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"290"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization to the date of death. A participant who has not died will be censored at last known date alive. OS will be followed continuously while participants are on the study drug and every 3 months via in-person or phone contact after participants discontinue the study drug. Median computed using Kaplan-Meier method. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until December 17, 2021).","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"OG001","title":"Docetaxel"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to the date of death or last known date alive (up to approximately 110 months)","title":"Overall Survival (OS) - Extended Collection","type":"POST_HOC","unitOfMeasure":"Months"}